Trial Profile
A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretroviral naïve Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SSAT066 Renal Integrase Study
- 03 Feb 2020 Results (N=93), analysis of the data pooled from 4 trials(3 phase I studies NCT02219217, NCT02509195 and NCT03094507 and one Phase III NCT02351908) assessing genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics, published in the Journal of Antimicrobial Chemotherapy
- 27 Oct 2017 Results presented at the 16th European AIDS Conference
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.